Anti-PEG Antibody Expressing Cells for PEG Quantification

The patent introduces an anti-PEG antibody as an intermediary component. Instead of directly detecting PEG-modified proteins, the method first detects the PEG moiety using anti-PEG antibody, which then serves as a mediator to enable subsequent detection steps. This intermediary approach allows detection of PEGylated molecules even when the original protein epitopes are obscured by PEG modification.

The patent employs cell-based ELISA methods that use cultured cells expressing anti-PEG antibodies instead of ascites-derived antibodies. This approach uses renewable, cost-effective cell cultures rather than expensive and regulated animal-derived products, thereby eliminating regulatory prohibitions and reducing costs while maintaining manufacturing feasibility.

The patent replaces the radioactive detection system with an enzymatic detection system using HRP (horseradish peroxidase) and colorimetric substrates. This substitution eliminates radioactive materials and associated safety requirements while maintaining high detection sensitivity through enzyme-catalyzed color development that can be measured by standard plate readers, making the method accessible to any laboratory without special radioactive handling facilities.

The patent uses anti-PEG antibody as a specific intermediary that selectively binds to PEG moieties on PEGylated molecules. This specific binding allows direct detection in complex protein mixtures without requiring prior removal of other proteins, as the anti-PEG antibody specifically targets the PEG component regardless of the attached protein. This intermediary approach dramatically improves sensitivity to the nano-gram level while eliminating complex sample preparation steps.